ENTITY

Cloudbreak Pharma (2592 HK)

4
Analysis
Health Care • United States
Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company dedicated to developing novel and differentiated treatments for eye diseases, leveraging its proprietary Multi-Kinase Inhibitor (MKI) platform. Its pipeline includes lead candidates such as CBT-001 for pterygium and CBT-004 for pinguecula, both in late-stage clinical trials. The company was founded in 2015 and is headquartered in Irvine, California, USA, with operations also in Mainland China and Hong Kong.
more
•18 Sep 2026 12:02

Cloudbreak Pharma (2592 HK): Synthetic Expert Call Transcript (18 Sep 2026)

SFC Suspension Driven by pre-IPO Put Options: The SFC’s rare Section 8(1) trading suspension on September 10, 2026, stems from suspected...

Share
•17 Sep 2026 14:32

Cloudbreak Pharma (2592 HK)'s Wipeout

Cloudbreak is suspended by the SFC, so there is nothing to do right now. This insight is somewhat of a vanity project just to get a handle on what...

Logo
108 Views
Share
•14 Sep 2026 11:44•Syndicated

CX Daily: China’s Diagnostic Firms Bet on a New Front in Global Health

In Depth: China’s Diagnostic Firms Bet on a New Front in Global Health (Johannesburg, South Africa) — For years, funding for global...

Logo
95 Views
Share
bullish•Kakaku.com Inc
•20 Sep 2026 06:10

Last Week In Event SPACE: Kakaku, Northern Star Resources, BASE Inc, Reliance Worldwide, Cloudbreak

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
95 Views
Share
No more insights
x